BACKGROUND: Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown. METHODS: We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens. RESULTS: The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens. DISCUSSION: Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons.
BACKGROUND: Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infectedpatients is unknown. METHODS: We evaluated the impact of NFV on cancer development in a large cohort of HIV-infectedpersons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens. RESULTS: The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens. DISCUSSION: Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infectedpersons.
Authors: L P Jacobson; T E Yamashita; R Detels; J B Margolick; J S Chmiel; L A Kingsley; S Melnick; A Muñoz Journal: J Acquir Immune Defic Syndr Date: 1999-08-01 Impact factor: 3.731
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Gary M Clifford; Jerry Polesel; Martin Rickenbach; Luigino Dal Maso; Olivia Keiser; Andreas Kofler; Elisabetta Rapiti; Fabio Levi; Gernot Jundt; Thomas Fisch; Andrea Bordoni; Daniel De Weck; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Anjali K Gupta; George J Cerniglia; Rosemarie Mick; W Gillies McKenna; Ruth J Muschel Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701
Authors: Cecilia Sgadari; Giovanni Barillari; Elena Toschi; Davide Carlei; Ilaria Bacigalupo; Sara Baccarini; Clelia Palladino; Patrizia Leone; Roberto Bugarini; Laura Malavasi; Aurelio Cafaro; Mario Falchi; Donatella Valdembri; Giovanni Rezza; Federico Bussolino; Paolo Monini; Barbara Ensoli Journal: Nat Med Date: 2002-03 Impact factor: 53.440
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: David C Boettiger; Caroline A Sabin; Andrew Grulich; Lene Ryom; Fabrice Bonnet; Peter Reiss; Antonella d'arminio Monforte; Ole Kirk; Andrew Phillips; Mark Bower; Gerd Fätkenheuer; Jens D Lundgren; Matthew Law Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Andrew C Hoover; Mohammed M Milhem; Carryn M Anderson; Wenqing Sun; Brian J Smith; Henry T Hoffman; John M Buatti Journal: Head Neck Date: 2014-06-18 Impact factor: 3.147